Literature DB >> 30026343

Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in in vitro and ex vivo models.

Enrica Borsi1, Marina Martello1, Barbara Santacroce1, Elena Zamagni1, Paola Tacchetti1, Lucia Pantani1, Katia Mancuso1, Serena Rocchi1, Michele Cavo2, Carolina Terragna1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30026343      PMCID： PMC6269297          DOI： 10.3324/haematol.2017.186924

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

1.  Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.

Authors:  Y Nefedova; T H Landowski; W S Dalton
Journal:  Leukemia       Date:  2003-06       Impact factor: 11.528

2.  Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma.

Authors:  Chang-Xin Shi; Klaus Martin Kortüm; Yuan Xiao Zhu; Patrick Jedlowski; Laura Bruins; Esteban Braggio; A Keith Stewart
Journal:  Haematologica       Date:  2015-05-14       Impact factor: 9.941

3.  The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro.

Authors:  W C Cheung; B Van Ness
Journal:  Leukemia       Date:  2001-02       Impact factor: 11.528

4.  Clonal competition with alternating dominance in multiple myeloma.

Authors:  Jonathan J Keats; Marta Chesi; Jan B Egan; Victoria M Garbitt; Stephen E Palmer; Esteban Braggio; Scott Van Wier; Patrick R Blackburn; Angela S Baker; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar; John D Carpten; Michael Barrett; Rafael Fonseca; A Keith Stewart; P Leif Bergsagel
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

Review 5.  Growth factors and antiapoptotic signaling pathways in multiple myeloma.

Authors:  N W C J van de Donk; H M Lokhorst; A C Bloem
Journal:  Leukemia       Date:  2005-12       Impact factor: 11.528

Review 6.  Biology and treatment of myeloma.

Authors:  Annamaria Brioli; Lorenzo Melchor; Brian A Walker; Faith E Davies; Gareth J Morgan
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-09

Review 7.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.

Authors:  Teru Hideshima; Constantine Mitsiades; Giovanni Tonon; Paul G Richardson; Kenneth C Anderson
Journal:  Nat Rev Cancer       Date:  2007-08       Impact factor: 60.716

8.  The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.

Authors:  Gang Lu; Richard E Middleton; Huahang Sun; MarkVic Naniong; Christopher J Ott; Constantine S Mitsiades; Kwok-Kin Wong; James E Bradner; William G Kaelin
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

9.  Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding.

Authors:  Jiro Kikuchi; Naoya Shibayama; Satoshi Yamada; Taeko Wada; Masaharu Nobuyoshi; Tohru Izumi; Miyuki Akutsu; Yasuhiko Kano; Kanako Sugiyama; Mio Ohki; Sam-Yong Park; Yusuke Furukawa
Journal:  PLoS One       Date:  2013-04-11       Impact factor: 3.240

10.  Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma.

Authors:  Enrica Borsi; Giulia Perrone; Carolina Terragna; Marina Martello; Angela F Dico; Giancarlo Solaini; Alessandra Baracca; Gianluca Sgarbi; Gianandrea Pasquinelli; Sabrina Valente; Elena Zamagni; Paola Tacchetti; Giovanni Martinelli; Michele Cavo
Journal:  Oncotarget       Date:  2014-04-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.